Ironshore Pharmaceuticals and Development, Inc Report issue

For profit Phase 2 Phase 3
Founded: Toronto Canada (2008)
Status: No NME R&D (2008)

Organization Overview

First Clinical Trial
2013
NCT01886469
First Marketed Drug
2018
methylphenidate (ritalin)
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

IRONSHORE PHARMS

Active Ingredients

Marketed Drugs (1)

methylphenidate (ritalin) (2018)

Drugs in Phase 3 Trials (1)

methylphenidate (ritalin) (4 trials)

Drugs in Phase 2 Trials (1)

dextroamphetamine (Dexedrine) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Attention Deficit Disorder with Hyperactivity (Phase 3)

Hyperkinesis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 2